Payment overview · 2025
General Payments
$254.97
15 reported records · 5 companies
Healthcare provider profile · identity verified
Todd Robertson Chace, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ENGLEWOOD, FL · NPI 1750428660
Verified facts
What the public records show
CMS Open Payments records show Todd Robertson Chace, D.O. received $254.97 in general payments during 2025 across 15 reported records.
Amgen Inc. accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.84 | 39.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.66 | 28.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.61 | 19.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.77 | 8.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.09 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.97 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.96 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.17 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.17 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.61 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.46 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 830 | 259 |
| Levothyroxine Sodium | Levothyroxine Sodium | 665 | 196 |
| Lisinopril | Lisinopril | 610 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 589 | 188 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 482 | 162 |
| Metformin Hcl | Metformin Hcl | 414 | 120 |
| Omeprazole | Omeprazole | 411 | 125 |
| Simvastatin | Simvastatin | 365 | 118 |
| Losartan Potassium | Losartan Potassium | 360 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 122 |
| Tamsulosin Hcl | Tamsulosin Hcl | 331 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 312 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 105 |
| Alprazolam | Alprazolam | 294 | 56 |
| Trazodone Hcl | Trazodone Hcl | 276 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 272 | 79 |
| Allopurinol | Allopurinol | 271 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 271 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 229 | 68 |
| Temazepam | Temazepam | 220 | 42 |
| Potassium Chloride | Potassium Chloride | 211 | 68 |
| Furosemide | Furosemide | 204 | 63 |
| Lorazepam | Lorazepam | 200 | 34 |
| Tramadol Hcl | Tramadol Hcl | 200 | 62 |
| Eliquis | Apixaban | 192 | 50 |
| Gabapentin | Gabapentin | 190 | 65 |
| Citalopram Hbr | Citalopram Hydrobromide | 187 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 178 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 171 | 58 |
| Meloxicam | Meloxicam | 170 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 61 |
| Ezetimibe | Ezetimibe | 158 | 50 |
| Finasteride | Finasteride | 150 | 41 |
| Sertraline Hcl | Sertraline Hcl | 149 | 51 |
| Famotidine | Famotidine | 137 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 29 |
| Atenolol | Atenolol | 123 | 40 |
| Clonazepam | Clonazepam | 120 | 26 |
| Metformin Hcl Er | Metformin Hcl | 113 | 34 |
| Glimepiride | Glimepiride | 112 | 31 |
| Spironolactone | Spironolactone | 109 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 27 |
| Memantine Hcl | Memantine Hcl | 92 | 19 |
| Montelukast Sodium | Montelukast Sodium | 86 | 27 |
| Buspirone Hcl | Buspirone Hcl | 85 | 27 |
| Carvedilol | Carvedilol | 78 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 22 |
| Prednisone | Prednisone | 73 | 34 |
| Azithromycin | Azithromycin | 71 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 16 |
| Donepezil Hcl | Donepezil Hcl | 69 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 21 |
| Meclizine Hcl | Meclizine Hcl | 66 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 20 |
| Farxiga | Dapagliflozin Propanediol | 63 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 11 |
| Bumetanide | Bumetanide | 62 | 23 |
| Mirtazapine | Mirtazapine | 62 | 22 |
| Synthroid | Levothyroxine Sodium | 61 | 20 |
| Benazepril Hcl | Benazepril Hcl | 59 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 19 |
| Lovastatin | Lovastatin | 54 | 17 |
| Valacyclovir | Valacyclovir Hcl | 51 | 19 |
| Valsartan | Valsartan | 51 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Estradiol | Estradiol | 48 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 12 |
| Primidone | Primidone | 48 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 14 |
| Mupirocin | Mupirocin | 44 | 37 |
| Sucralfate | Sucralfate | 44 | 25 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 43 | suppressed |
| Levetiracetam | Levetiracetam | 43 | 14 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Jantoven | Warfarin Sodium | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 16 |
| Warfarin Sodium | Warfarin Sodium | 38 | 11 |
| Fenofibrate | Fenofibrate | 37 | 12 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 33 |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Digoxin | Digoxin | 35 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 35 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Ozempic | Semaglutide | 33 | 11 |
| Xarelto | Rivaroxaban | 33 | 12 |
| Irbesartan | Irbesartan | 32 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 16 |
| Ramipril | Ramipril | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 23 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 14 |
| Naproxen | Naproxen | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 13 |
| Torsemide | Torsemide | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | 11 |
| Cephalexin | Cephalexin | 26 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | 13 |
| Baclofen | Baclofen | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 12 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.97 · 15 records | Amgen Inc. | AIRSUPRA, EVENITY, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error